Lexicon Pharmaceuticals (LXRX)

• Market cap: $273M
• 1 day: -7.71%
• 5 days: -23.62%
• 1 month: 2.40%
• 3 months: -38.02%
• 6 months: -66.39%
• Year to date: -2.69%
• 1 year: -59.56%
• 5 years: -75.53%
• 10 years: -88.00%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Employees: 285

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

745% more call options, than puts

Call options by funds: $2.34M | Put options by funds: $277K

105% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 22

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

8% more funds holding

Funds holding: 127 [Q2] → 137 (+10) [Q3]

1.93% more ownership

Funds ownership: 77.93% [Q2] → 79.87% (+1.93%) [Q3]

5% less capital invested

Capital invested by funds: $476M [Q2] → $453M (-$22.4M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4 429% upside
• Avg. target: $4 429% upside
• High target: $4 429% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 26% 1-year accuracy 104 / 406 met price target

429% upside $4

Buy Reiterated

29 Jan 2025